These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32880385)

  • 21. Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.
    Li H; Xiao N; Li Z; Wang Q
    Tohoku J Exp Med; 2017 Feb; 241(2):165-173. PubMed ID: 28202851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction and validation of a prognostic model for overall survival time of patients with ovarian cancer by metabolism-related genes.
    Kong D; Guo H
    J Obstet Gynaecol Res; 2024 Sep; 50(9):1622-1639. PubMed ID: 39098991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and validation of a metabolic-related genes prognostic model for oral squamous cell carcinoma based on bioinformatics.
    Zhang J; Ma C; Qin H; Wang Z; Zhu C; Liu X; Hao X; Liu J; Li L; Cai Z
    BMC Med Genomics; 2022 Dec; 15(1):269. PubMed ID: 36566175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
    Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
    Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zinc Finger Protein 24 is a Prognostic Factor in Ovarian Serous Carcinoma.
    Chen J; Guo J; Yuan Y; Wang Y
    Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):136-144. PubMed ID: 34608874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.
    He J; Liu Y; Zhang L; Zhang H
    Med Sci Monit; 2018 Dec; 24():8933-8940. PubMed ID: 30531684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of a metabolism-related gene expression prognostic model in endometrial carcinoma patients.
    Jiang P; Sun W; Shen N; Huang X; Fu S
    BMC Cancer; 2020 Sep; 20(1):864. PubMed ID: 32894095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
    Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
    Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
    Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
    Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased Expression of LYNX1 in Ovarian Serous Cystadenocarcinoma Predicts Poor Prognosis.
    Liu H; Wang A; Ma Y
    Biomed Res Int; 2020; 2020():1392674. PubMed ID: 33299855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis.
    An Y; Yang Q
    Biomed Res Int; 2020; 2020():7594098. PubMed ID: 33381581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer.
    Schwede M; Waldron L; Mok SC; Wei W; Basunia A; Merritt MA; Mitsiades CS; Parmigiani G; Harrington DP; Quackenbush J; Birrer MJ; Culhane AC
    Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):509-519. PubMed ID: 31871106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.